TrioxBio Announces Fast Track Designation Granted by U.S. FDA to Raviten(R) for the Treatment of Intradialytic Hypotension

Phase II clinical trials in patients undergoing hemodialysis to be initiated in Q4, 2018 NEWARK, Delaware, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- TrioxBio Inc., a clinical-stage biopharmaceutical company specializing in the developme... Biopharmaceuticals, FDA TrioxBio, Raviten, ethylisothiouronium, Intradialytic Hypotension, hemodialysis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news